Revolution Medicines Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Revolution Medicines Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- RVMD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001628171
Board of directors
- Since 2023
-
Barbara Weber · DirectorSince 2023
-
Elizabeth M. Anderson · DirectorSince 2023
-
Eric Thomas Schmidt · DirectorSince 2023
-
Flavia Borellini · DirectorSince 2023
-
Frank Clyburn · DirectorSince 2024
-
Lorence H. Kim · DirectorSince 2023
-
Mark A. Goldsmith · Director · See RemarksSince 2023
-
Sandra Horning · DirectorSince 2023
-
Sushil Patel · DirectorSince 2023
-
Thilo Schroeder · DirectorSince 2023
Board connections
9 of this board's directors also sit on 14 other boards.
- via Frank Clyburn and Lorence H. Kim
- via Alexis Borisy and Barbara Weber
- via Alexis Borisy and Barbara Weber
- via Elizabeth M. Anderson
- via Sandra Horning
- via Elizabeth M. Anderson
- via Frank Clyburn
- via Sandra Horning
- via Alexis Borisy
- via Sandra Horning
- via Flavia Borellini
- via Alexis Borisy
- via Eric Thomas Schmidt
- via Sushil Patel
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $154,531,468
- 154 sales by 12 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Elizabeth M. Anderson Director | Option exercise | +5,070 | $1.12 | $5,678 |
| Sep 22, 2026 | Elizabeth M. Anderson Director | Open-market sale | −910 | $191.85 | $174,585 |
| Sep 22, 2026 | Elizabeth M. Anderson Director | Open-market sale | −4,985 | $192.54 | $959,805 |
| Sep 22, 2026 | Elizabeth M. Anderson Director | Open-market sale | −2,648 | $193.44 | $512,227 |
| Sep 22, 2026 | Elizabeth M. Anderson Director | Open-market sale | −1,500 | $194.59 | $291,883 |
| Sep 22, 2026 | Elizabeth M. Anderson Director | Open-market sale | −100 | $195.15 | $19,515 |
| Sep 18, 2026 | Mancini Anthony Officer (See Remarks) | Open-market sale | −1,764 | $196.94 | $347,402 |
| Sep 16, 2026 | Anders Jack Officer (Chief Financial Officer) | Open-market sale | −61 | $195.00 | $11,895 |
| Sep 16, 2026 | Cislini Jeff Officer (SVP & General Counsel) | Open-market sale | −52 | $195.01 | $10,140 |
| Sep 16, 2026 | Mark A. Goldsmith Director, Officer (See Remarks) | Open-market sale | −213 | $195.01 | $41,537 |
| Sep 16, 2026 | Horn Margaret A Officer (Chief Operating Officer) | Open-market sale | −76 | $195.01 | $14,821 |
| Sep 16, 2026 | Kelsey Stephen Michael Officer (See Remarks) | Open-market sale | −85 | $195.01 | $16,576 |
| Sep 16, 2026 | Mancini Anthony Officer (See Remarks) | Open-market sale | −27 | $195.05 | $5,266 |
| Sep 16, 2026 | Alan B. Sandler Officer (Chief Development Officer) | Open-market sale | −5 | $194.96 | $975 |
| Sep 16, 2026 | Anders Jack Officer (Chief Financial Officer) | Open-market sale | −3,992 | $199.30 | $795,618 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.